Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.470
0.00 (0.00%)
At close: Nov 7, 2025, 4:00 PM EST
1.420
-0.050 (-3.40%)
After-hours: Nov 7, 2025, 7:59 PM EST
Aptevo Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Aptevo Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Aptevo Therapeutics.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $11,100 → $5,920 | Strong Buy | Maintains | $11,100 → $5,920 | +402,621.09% | Sep 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $2,246,640 → $651,200 | Buy | Maintains | $2,246,640 → $651,200 | +44,299,219.73% | May 13, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $2,083,840 → $1,628,000 | Strong Buy | Maintains | $2,083,840 → $1,628,000 | +110,748,199.32% | May 28, 2021 |
| Piper Sandler | Piper Sandler | Buy Maintains $1,041,920 → $2,246,640 | Buy | Maintains | $1,041,920 → $2,246,640 | +152,832,553.06% | Nov 11, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $5,470,080 | Strong Buy | Initiates | $5,470,080 | +372,114,185.71% | Apr 11, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-14.46
from -1.75K
EPS Next Year
-7.57
from -14.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.89 | -7.79 | |||
| Avg | -14.46 | -7.57 | |||
| Low | -13.90 | -7.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.